Krejcí M, Doubek M, Adam Z, Hájek R, Vorlícek J, Mayer J
II. interní klinika FNsP, Brno-Bohunice.
Vnitr Lek. 1997 Nov;43(11):756-8.
High dosage melfalan chemotherapy with subsequent autologous blood stem cell transplantation in suitably selected patients with multiple myeloma greatly increases the probability that complete remission will be achieved and it prolongs the mean survival period as compared with classical chemotherapy. Till recently patients with multiple myeloma and renal insufficiency were not included in transplantation programmes. Only recently several papers were published abroad which indicate the possibility to implement transplantations also in these patients. The authors describe the treatment, incl. the first autologous transplantation of blood stem cells in a patient with multiple myeloma and renal insufficiency.
对于经过适当挑选的多发性骨髓瘤患者，高剂量美法仑化疗并随后进行自体血干细胞移植，与传统化疗相比，能大大提高实现完全缓解的概率，并延长平均生存期。直到最近，患有多发性骨髓瘤和肾功能不全的患者都未被纳入移植项目。就在最近，国外发表了几篇论文，表明在这些患者中也有可能进行移植。作者描述了该治疗方法，包括对一名患有多发性骨髓瘤和肾功能不全的患者进行首次自体血干细胞移植。
